Newsflash:
- Many Drug Labels Missing Dose, Safety Info for Kids
- Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
- J&J Opens Doxil Rationing Program to New Patients
- FDA Issues Safety Label Changes for Fingolimod
- FDA Backs Pill to Block HIV Infection
- FDA Advisers Recommend Approving Arena Weight-Loss Drug
Merck CEO: After Tough Debut in 2011, 2012 Will See Drugs Nearing Approval, Late-Stage Deals
Associated Press (01/05/12)
Merck CEO Kenneth Frazier said that setbacks in drug development and other problems made his just-ended first year a tough debut but that he expects better news in 2012. Speaking to analysts at the Goldman Sachs’ Healthcare CEO’s Unscripted conference in New York, he said some important new drugs are on the horizon and Merck is pursuing deals for others in late testing.
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
